Vatalanib dihydrochloride

HCID 22386467

Grundinformationen

CAS
212141-51-0
Standard-SMILES
Cl.Cl.Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
InChIKey
AZUQEHCMDUSRLH-UHFFFAOYSA-N
Summenformel
C20H17Cl3N4
Durchschnittliche Molmasse
419,7 g/mol
Monoisotopische Masse
418,05187958

Überblick

Vatalanib dihydrochloride is a member of phthalazines.

Namen und Bezeichner

Bevorzugter Name
Vatalanib dihydrochloride
IUPAC
N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochloride
Englischer Name
Vatalanib Dihydrochloride
Summenformel
C20H17Cl3N4
Molmasse
419.74

Namen und Synonyme

Vatalanib dihydrochloride212141-51-0DTXSID5049073DTXCID6028999RefChem:388334Vatalanib 2HClVatalanib (PTK787) 2HClN-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine dihydrochloridePTK/ZKVatalanib HClN-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine DihydrochlorideVatalanib (dihydrochloride)
Weitere Namen anzeigen
CS-465CGP-79787ZK-222584CGP-79787DCGP79787) 2HClVatalinib 2HClPTK787 dihydrochlorideVatalanib 2HCl (PTK787)
s1101AKOS005146306NCGC00181350-02AS-58428N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochlorideVatalanib?3AMG9AK8TJEC-000.2362

Datenbank-Bezeichner

CAS
212141-51-0
PubChem CID
22386467
DTXSID
DTXSID5049073
ChEMBL
CHEMBL2142861
ChEBI
CHEBI:228537
UNII
3AMG9AK8TJ

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
50,7 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
4
Schwere Atome
27

Physikochemische Eigenschaften

Schmelzpunkt
268 · 268-2700C
storage temp.
-20 °C · Inert atmosphere,Store in freezer, under -20°C
Löslichkeit
Soluble in DMSO (up to 20 mg/ml with warming) or in Water (up to 100 mg/ml)
Aggregatzustand
solid
Farbe
White or off-white
Wasserlöslichkeit
2 O: · H2O: 2mg/mL, clear

Sicherheit und Regulatorisches

Sicherheitsdaten

wgk
WGK 3
hs_code
29333990
risk_code
36/37/38
safety_code
24/25
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Anwendungen · 2 Einträge

BeschreibungVatalanib is an antagonist of the VEGF receptors, inhibiting the receptor tyrosine kinase activities of VEGFR1 (Flt1), VEGFR2 (KDR), and VEGFR3 (Flt4) with IC50 values of 77, 37, and 190 nM, respectively. It less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on a large panel of additional kinases. Vatalanib completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice, suggesting its use in diabetic retinopathy and other diseases featuring aberrant vascular development.

VerwendenVascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Antineoplastic.

Anbieter91 Anbieter

上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
上海凌富药物研究有限公司+86(21)5895 0110 19945755304 · [email protected]
南通飞宇生物科技有限公司0513-68819626 15152877458 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
上海麦克林生化科技股份有限公司021-50706066 15221275939 · [email protected]

Zugehörige Reaktionen

8

Notizen zur Verbindung

Wird geladen…